tbuckley/cabot-search huggingface dataset:
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure
Authors: Andrew Sumarsono, Muthiah Vaduganathan, Ezimamaka Ajufo, Ann Marie Navar, Gregg C. Fonarow, Sandeep R. Das, Ambarish Pandey
Journal: JAMA Cardiology (2019)

<h3>Importance</h3> In 2015, the US Food and Drug Administration approved 2 new medications for treatment of heart failure with reduced ejection fraction, sacubitril/valsartan and ivabradine. However, few national data are available examining their contemporary use and associated costs. <h3>Objective</h3> To evaluate national patterns of use of sacubitril/valsartan and ivabradine and associated therapeutic spending in Medicare Part D and Medicaid. <h3>Design, Setting, and Participants</h3> In this US nationwide claims-based study, we analyzed data from the Medicare Part D Prescription Drug Event and Medicaid Utilization and Spending data sets to compare national patterns of use of sacubitril/valsartan and ivabradine between 2016 and 2017. <h3>Main Outcomes and Measures</h3> Changes in total spending, per-beneficiary/claim spending, number of beneficiaries, and number of claims between 2016 and 2017 for sacubitril/valsartan and ivabradine. <h3>Results</h3> The number of Medicare beneficiaries prescribed sacubitril/valsartan increased from 35 423 to 90 606 (156% increase from 2016 to 2017). Medicare beneficiaries prescribed ivabradine increased from 15 856 to 23 213 (46% increase). In 2017, Medicare Part D spent $227 million and $7.3 million on sacubitril/valsartan and ivabradine, respectively. This represented increases of 241% and 59% compared with 2016 spending, respectively. The annual Medicare per-beneficiary spending on sacubitril/valsartan and ivabradine was $2512 and $2400. Parallel trends in use patterns and spending were observed among Medicaid beneficiaries. <h3>Conclusions and Relevance</h3> Although initial experiences suggested slow uptake after regulatory approval, these national data demonstrate an increase in use of sacubitril/valsartan and, to a lesser degree, ivabradine in the United States. Current annual per-beneficiary expenditures remain less than spending thresholds that have been reported to be cost-effective. Ongoing efforts are needed to promote high-value care while improving affordability and access to established and emerging heart failure therapies.
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis
Authors: Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini
Journal: Blood (2019)
Personal use of drug samples by physicians and office staff
Authors: J. T. Chiu
Journal: JAMA (1997)

To the Editor.  —If the agony of Dr Westfall and colleagues 1 over personal use of drug samples were indeed pertinent, Shen Nung, who purportedly founded Chinese herbal medicine by testing hundreds of potentially medicinal plants, would have been the first known offender. 2 It is naive to believe that such practice, even if adopted universally by all health care professionals, will make a quark of difference in drug cost. If Westfall et al care to probe further, they will find that a drug's price is more closely related to that of its closest competitors and bears little relationship to its actual manufacturing cost. In fact, these same companies can still make a profit by selling their products at a fraction of the domestic price just a few paces from our borders.  No one should be so cynical as to believe that a physician would use a drug on himself or herself just
Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Authors: Christopher Pleyer, Jeffrey Cohen, Susan Soto, Mir Ali, Inhye E Ahn, Pia Nierman, Janet Valdez, Jennifer Lotter, Jeanine Superata, Xin Tian, Adrian Wiestner, Clare Sun
Journal: Blood (2019)
Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination
Authors: Po-Ming Chen, Wen-Yu Pan, Cheng-Yu Wu, Ching-Yen Yeh, Chiranjeevi Korupalli, Po-Kai Luo, Chun-Ju Chou, Wei-Tso Chia, Hsing-Wen Sung
Journal: Biomaterials (2019)
Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features
Authors: Yanmeng Li, Xiao Li, Hao Li, Yifan Zhao, Ziyang Liu, Kunkun Sun, Xiang Zhu, Qingyi Qi, Bei An, Danhua Shen, Ruoyan Li, Taorui Liu, Jiahui Mi, Lientu Wang, Fan Yang, Fan Bai, Jun Wang
Journal: European Respiratory Journal (2019)

Background Lung adenocarcinomas (LUADs) that display radiologically as subsolid nodules (SSNs) exhibit more indolent biological behaviour than solid LUADs. SSNs, commonly encompassing pre-invasive and invasive yet early-stage adenocarcinomas, can be categorised as pure ground-glass nodules and part-solid nodules. The genomic characteristics of SSNs remain poorly understood. Methods We subjected 154 SSN samples from 120 treatment-naïve Chinese patients to whole-exome sequencing. Clinical parameters and radiological features of these SSNs were collected. The genomic landscape of SSNs and differences from that of advanced-stage LUADs were defined. In addition, we investigated the intratumour heterogeneity and clonal relationship of multifocal SSNs and conducted radiogenomic analysis to link imaging and molecular characteristics of SSNs. Fisher's exact and Wilcoxon rank sum tests were used in the statistical analysis. Results The median somatic mutation rate across the SSN cohort was 1.12 mutations per Mb. Mutations in EGFR were the most prominent and significant variation, followed by those in RBM10 , TP53 , STK11 and KR A S . The differences between SSNs and advanced-stage LUADs at a genomic level were unravelled. Branched evolution and remarkable genomic heterogeneity were demonstrated in SSNs. Although multicentric origin was predominant, we also detected early metastatic events among multifocal SSNs. Using radiogenomic analysis, we found that higher ratios of solid components in SSNs were accompanied by significantly higher mutation frequencies in EGFR , TP53 , RBM10 and ARID1B , suggesting that these genes play roles in the progression of LUADs. Conclusions Our study provides the first comprehensive description of the mutational landscape and radiogenomic mapping of SSNs.
Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?
Authors: Tohru Fujiwara, Chie Suzuki, Tetsuro Ochi, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Yukio Nakamura, Hideo Harigae
Journal: Blood (2019)
Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study
Authors: Marc Michel, Marco Ruggeri, Tomás José González-López, Stephane Cheze, Waleed Ghanima, Tor Henrik Anderson Tvedt, Mikael Ebbo, James B. Bussel, Bertrand Godeau
Journal: Blood (2019)
Genomic Landscape of Juvenile Myelomonocytic Leukemia: A Real World Context
Authors: Gaurav Chatterjee, Gaurav Narula, Shrinidhi Nathany, Prashant Tembhare, Papagudi Ganesan Subramanian, Sumeet Gujral, Maya Prasad, Nirmalya Roy Moulik, Vasudev Bhat, Chetan A. Dhamne, Shripad Banavali, Nikhil Patkar
Journal: Blood (2019)
Study Identifies Primary Care Knowledge Gaps and Barriers in Type 2 Diabetes Prevention
Authors: Rebecca Voelker
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study
Authors: David Cella, Jan McKendrick, Harrison Davis, Ravi Vij, Clara Chen
Journal: Blood (2019)
Abnormal Cytokine Production By Mast Cell Cultures from Sickle Cell Anemia Patients in Response to Inflammatory Stimuli and to Co-Culture with Eosinophils
Authors: Myriam Salazar-Terreros, Kleber Yotsumoto Fertrin, Nicolas Moreno Reyes, Fernando Ferreira Costa, Carla F. Franco-Penteado
Journal: Blood (2019)
Ante-partum Haemorrhage--1
Authors: J. S. Scott
Journal: BMJ (1964)

Ante-partum haemorrhage (A.P.H.) is one of the gravest -obstetric emergencies; with dramatic suddenness a pregnant patient can become exsanguinated to the verge of death and iher baby may die.Unlike post-partum haemorrhage, which is always preceded by the adequate warning mechanism of labour, A.P.H. often occurs without warning.
FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial
Authors: Chiawei Chang, Sjoukje Van Der Stegen, Mandal Mili, Raedun Clarke, Yi-Shin Lai, Alec Witty, Pieter Lindenbergh, Bi-Huei Yang, Mushtaq Husain, Helena Shaked, Brian Groff, Laurel Stokely, Ramzey Abujarour, Tom Lee, Hui-Yi Chu, Mochtar Pribadi, Jason ORourke, Alma Gutierrez, Isabelle Riviere, Michel Sadelain, Bahram Valamehr
Journal: Blood (2019)
HOUT-04. ASSOCIATION OF COMMON PATIENT-REPORTED IMMUNOTHERAPY SYMPTOMATIC SIDE EFFECTS AND PSEUDOPROGRESSION IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Authors: Yamini Vyas, Elizabeth Vera, Christine Bryla, Sonja Crandon, Jing Wu, Kathleen Wall, Brett Theeler, Christine Siegel, Jennifer Reyes, Marta Penas-Prado, Nicole Leggiero, Christine Cordova, Eric Burton, Ramya Antony, Lisa Boris, Orwa Aboud, Mark Gilbert, Terri Armstrong
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Immunotherapy agents have unique symptomatic side effects; patient-reported outcomes (PROs) can help to characterize the benefits and burdens associated with therapy. Common immunotherapy-associated symptoms include pain, fatigue, shortness of breath, and irregular bowel patterns. The purpose of this study was to assess the severity of symptoms and their association with imaging changes in CNS tumor patients undergoing single agent or combination treatment with immune checkpoint inhibitors (ICIs). METHODS Patients completed the MDASI-BT or MDASI-SP at baseline and longitudinally (every 8 weeks), and results through cycle 4 are reported. Neuro-imaging was categorized as stable, possible ICI-related pseudoprogression, or progression by clinical team review. RESULTS 29 Brain Tumor (BT) and 6 Spinal Tumor patients participated; the majority of which were male (62%) and white (91%), ranging 24-74yo (mean = 46). Glioblastoma was the most common diagnosis (31%) followed by medulloblastoma (16%), with 56% of patients having greater than 2 recurrences prior to the study. At baseline, both brain and spine tumor patients reported moderate to severe fatigue (Brain=4, Spine=6) and pain (Spine=5) with shortness of breath and pain worsening over time. BT patients with pseudoprogression were more likely to report increased fatigue (87%) and pain (63%) compared to those with stable (29%) or true progressive (17%) disease on imaging. BT patients with pseudoprogression also reported worsening of cognitive (43%) and neurologic (57%) symptom burden. CONCLUSIONS In contrast to the common pseudoprogression after chemoradiation, treatment-specific symptoms were worse with ICI-related pseudoprogression by MRI where an immunologic reaction was the likely cause of the imaging worsening. These results suggest that commonly used symptom and functional assessments to distinguish true progression from pseudoprogression may not be helpful with immunotherapy. Additional studies including those with pathologic confirmation of progression or pseudoprogression combined with outcomes measures are needed to develop more accurate determinations of disease status.
Outcomes of First-Line Treatment (FL) of Classical Hodgkin Lymphoma (cHL) in Argentina: A Real Life Multicenter Retrospective Study
Authors: Victoria Otero, Carolina Valeria Mahuad, Laura Korin, Enriqueta Martinez, Fernando Warley, Hernán García Rivello, Nancy Cristaldo, Dana Kohan, Marta Zerga, Gonzalo Martin Garate, Maria De Los Angeles Vicente Reparaz, Maria Florencia Aizpurua, Erica Rojas Bilbao, Susana Cerana, Maria Eugenia Funes, Iliana Plaza, Maria Cecilia Foncuberta, Anahí Vijnovich Baron, Santiago Cranco, Adriana Vitriu, Mariela Gomez, Justina Lavalle, Claudia Casali, Manuela Clavijo, Luciana Melillo, Maria Cecilia Cabral Lorenzo, Augusto Miroli, Laura Fishman, Maximiliano J. Pavlove, Marcela Miodosky, Silvana Cugliari
Journal: Blood (2019)
Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)
Authors: Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Kwak Jae-Yong, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Park Byeong Bae, Jae-Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Jeong Seong Hyun, Young-Woong Won, Byeong Seok Sohn, Jihyun Kwon, Cheolwon Suh, Won Seog Kim
Journal: Blood (2019)
Predicting the Long-Term Efficacy of Ifnα in JAK2V617F and Calr-Mutated MPN Patients
Authors: Amandine Tisserand, Robert Noble, Matthieu Mosca, Christophe Marzac, Gaelle Vertenoeil, Hugo Campario, Mira El-Khoury, Caroline Marty, Philippe Rameau, Nicole Casadevall, Eric Solary, Florence Pasquier, Hana Raslova, Bruno Cassinat, Stefan N Constantinescu, Jean-Jacques Kiladjian, Francois Girodon, Michael Hochberg, Villeval Jean-Luc, William Vainchenker, Isabelle Plo
Journal: Blood (2019)
Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)
Authors: Mohamed A Yassin, Mohammad Abdul-Jaber Abdulla, Feryal Abbas, Prem Chandra, Abdulqadir Jeprel Nashwan, Rola S Ghasoub, Nancy Kassem, Ahmad Al Sabbagh, Zafar Nawaz, Susanna Jane Akiki
Journal: Blood (2019)
Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma
Authors: Samantha Brocklehurst, Neil Desai, Jennifer L Shah, Syed Rizvi, Praveen Ramakrishnan Geethakumari, Kiran A Kumar
Journal: Blood (2019)
Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison
Authors: Pieter Sonneveld, Maria-Victoria Mateos, Adrián Alegre, Thierry Facon, Cyrille Hulin, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, Sarah Cote, Philippe Moreau
Journal: Blood (2019)
Genetics of Human Thyroid Cancer Cell Lines—Response
Authors: Iñigo Landa, Nikita Pozdeyev, Jeffrey A. Knauf, Bryan R. Haugen, James A. Fagin, Rebecca E. Schweppe
Journal: Clinical Cancer Research (2019)

We read with interest the letter by Garcia and colleagues, as well as their recent publication assessing MET amplification in the anaplastic thyroid cancer (ATC)-derived TTA-1 cell line (1). In their correspondence, the authors asked whether MET amplification was observed in TTA-1 cells in our study (2). We retrieved the specific data for MET in TTA-1 and compared it with other cell lines. As shown in Fig. 1A, TTA-1 was the only cell line displaying a focal MET amplification, which correlated with the highest mRNA expression levels (Fig. 1B). Furthermore, we looked at our unpublished data assessing phospho-protein levels in these specimens, showing that phospho-MET is significantly elevated in TTA-1 (Fig. 1C). We studied the earliest TTA-1 passage available in our laboratory and observed a MET copy number fold change = 11.1, whereas Garcia and colleagues reported 20 copies. These differences in copy number magnitude are likely attributable to the methods used for copy number calling (targeted sequencing vs. FISH) and, as the authors pointed out, to some degree of clonal evolution during passaging of cultured cells. Although we did not have access to the original tumor from which this cell line was derived 25 years ago (3), the nonoverlapping pattern of occurrence of MET amplification with other known thyroid cancer driver genes, the signaling consequences of this genetic event, along with our recent observation of Met amplification as a mechanism of resistance to Braf inhibition in murine ATCs (4), strongly suggests that MET activation is a genetic driver in the TTA-1 cell line, and perhaps in a subset of ATCs. To our knowledge, this is the first example of a thyroid cancer cell line driven by an oncogenic amplification event.No potential conflicts of interest were disclosed.See the original Letter to the Editor, p. 6882
Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab
Authors: Ann Forslund, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, James R. Berenson, Michael Robbins
Journal: Blood (2019)
SCIDOT-45. MAGNETIC FIELD STRUCTURE OF THE HÆLO™ PEDIATRIC SYSTEM
Authors: Eric Peterson, Xavier Figueroa, Mike Butters, Amanda Woodcock, Dan Brown, Ken Ferguson
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The Hælo pediatric system, an investigational medical device intended to treat diffuse midline glioma (DMG), emits a magnetic field intended to disrupt the growth of DMG tumors. The Hælo headcoil is positioned on the back of the patient’s head; the field envelopes the patient’s head and the specific frequencies of the field penetrate the skull and brain tissue without any significant attenuation. METHODS The shape and intensity of the magnetic field emitted by the Hælo headcoil were measured using a triaxial magnetic sensor, which measures the flux density along three orthogonal axes. The headcoil is designed to conform to the back of the head and is not planar. To account for the slight difference in field shape due to the coil’s convex shape, the field was measured with the coil held in both a convex and concave position relative to the central plane. A custom-designed measurement system was used to position the sensor in a three-dimensional grid with 1 cm resolution (approximately 10,000 individual measurements for each coil position.) A test field with the same flux density produced by the Hælo pediatric system treatment field was used. The root mean square of the field along each axis was calculated and combined to yield the total flux density at each position. The datasets from each coil position were combined to create a complete three-dimensional map of the field generated by the headcoil. RESULTS The greatest flux density is proximal to the coil. The test field ranged from approximately 200 mGauss near the headcoil to 100 mG within the ellipsoid formed by the headcoil. CONCLUSION The field of the Hælo pediatric system encompasses the brain and portions of the brainstem, and thus delivers a targeted magnetic therapeutic to the common tumor locations for DMG.
Primary Antigen Aberrations and Immunophenotype Shifts of Blasts in AML Patients during the Treatment and at the Time of Relapse
Authors: Tatiana I. Lobanova, Elena N. Parovichnikova, Irina V. Galtseva, Vera V. Troitskaya, Julia O. Davydova, Nikolay M. Kapranov, Andrey N. Sokolov, Sergei M. Kulikov, Valery G. Savchenko
Journal: Blood (2019)
NIMG-43. LONGITUDINAL TRACKING AND GROWTH RATE CHARACTERIZATION OF BRAIN METASTASES ON MAGNETIC RESONANCE IMAGING
Authors: Jay Patel, Andrew Beers, Ken Chang, James Brown, Katharina Hoebel, Bruce Rosen, Raymond Huang, Priscilla Brastianos, Elizabeth Gerstner, Jayashree Kalpathy-Cramer
Journal: Neuro-Oncology (2019)

Abstract PURPOSE Measuring treatment response is vital for assessing efficacy of treatment regimen for patients with brain metastases (BM). Unfortunately, manual delineation of all lesions on MRI across time-points is prohibitively time-consuming, making it infeasible to track individual lesion growth/shrinkage rates as part of the clinical workflow. To overcome this challenge, we propose a deep learning approach to segment all BM, and furthermore, show that certain brain regions are more prone to high-growth rate lesions. METHODS 163 longitudinal MRIs from 77 patients with MPRAGE-post contrast imaging protocol were prospectively obtained from Massachusetts General Hospital (MGH). An expert neuro-oncologist provided ground truth segmentations for all patients. A 3D U-Net architecture was trained to automatically segment BM; training was stopped when validation set Dice score plateaued to prevent overfitting. To enable lesion tracking, all time-points per patient were affinely registered to each other. Every lesion was subsequently classified based on its growth rate (responder: overall lesion shrinkage; inconclusive: 0% to 40% lesion growth; non-responder: more than 40% lesion growth). Characterization of global lesion growth rate patterns was accomplished by affinely registering all time-points to the MNI brain atlas. Segmented lesions were projected onto the atlas, which was qualitatively analyzed to identify spatial regions composed primarily of one class of lesion. RESULTS For automatic segmentation, we report a mean dice score of 0.778, 0.737, and 0.704 on training, validation, and testing sets respectively. Furthermore, we find that the largest BM with the highest average growth rate (non-responders) tend to be located in the posterior frontal/parietal lobes, while smaller, lower growth rate lesions (responders) tend to be localized in the frontal lobes. The posterior fossa was found to be heterogeneous in lesion size and growth rate. CONCLUSION We developed automatic metastatic lesion tracking over time-points and identified brain regions associated with differing growth rate lesions.
Annals Story Slam - Seven Extraordinary Words
Authors: Edward Etchells
Journal: Annals of Internal Medicine (2019)

Web Exclusives5 November 2019Annals Story Slam - Seven Extraordinary WordsFREEEdward Etchells, MD, MScEdward Etchells, MD, MScSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0022 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Seven Extraordinary Words "Seven Extraordinary Words," by Edward Etchells, MD, MSc (Duration 4:54)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2019Volume 171, Issue 9Page: SS1 ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...